+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years - 17Years
All Genders
ID04965675

Randomized Study to Evaluate Intravenous Eptinezumab for Preventing Chronic Migraine in Adolescents Ages 12-17

Led by H. Lundbeck A/S · Updated on 2026-10-16

285

Participants Needed

79

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating eptinezumab to see if it reduces the number of migraine days compared to a placebo in young people aged 12 to 17 with chronic migraine. This phase 3 study focuses on adolescents who have had chronic migraine for at least six months and aims to assess the preventive treatment effects of this intravenous drug. Participants are randomly assigned to one of three groups to receive a single intravenous infusion of either eptinezumab 300 mg, eptinezumab 100 mg, or a placebo. The doses are adjusted according to each participants body weight. The study includes a 4-week screening period, followed by a 12-week double-blind treatment phase, and ends with an 8-week safety follow-up period. During the study, participants will complete headache diaries and undergo evaluations to measure changes in monthly migraine days and other migraine-related outcomes. Researchers will also monitor blood levels of eptinezumab and immune responses. The total study participation lasts approximately 24 weeks, including screening, treatment, and safety follow-up phases.

CONDITIONS

Brief Title

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Research Team

E

Email contact via H. Lundbeck A/S

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here